Q-omics provides the consensus-scored IDUA profile across patient tissues and cancer cell-line models. IDUA expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IDUA is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, IDUA protein abundance shows 30,036 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where IDUA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IDUA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IDUA survival associations across molecular data types. IDUA RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IDUA RNA expression–survival associations across cancer types. High IDUA expression shows unfavorable associations in KIRC, UVM, OV, COAD and LGG, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IDUA RNA expression.
This table summarizes IDUA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IDUA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IDUA shows lower tumor expression in LUSC and higher tumor expression in KIRC, COAD, LIHC, KIRP and CHOL. The KIRC box plot shows higher IDUA RNA expression in tumor versus normal tissue (log2 FC = +0.752, t-test p < 0.001).
This table shows molecular features associated with IDUA in patient tissues and cancer cell lines. In patient samples, IDUA shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IDUA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
